Avidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle Energy
Avidity Biosciences’ antibody-oligonucleotide conjugate improved mobility and muscle power in a sort of muscular dystrophy in an early-stage trial, and...
Pharmaceutical Updates
RFK Jr appears to be like to change uncommon illness regulation by fast-tracking drug approvals
US well being secretary Robert F Kennedy Jr. needs to make sure the following the US doesn't lag behind different...
STAT+: Up and down the ladder: The newest comings and goings
Employed somebody new and thrilling? Promoted a rising star? Lastly solved that hard-to-fill spot? Share the information with us, and...
Perspective Therapeutics Brings Power to the Radiopharma World
It’s onerous to inform if Thijs Spoor and Michael Schultz are speaking quick as a result of they're enthusiastic about...
SCHOTT Pharma invests in RTU cartridge capability growth
The brand new facility in Hungary will create 100 native jobs. Credit score: SCHOTT Pharma. Drug containment and supply options...
GLP-1 medicine could also be linked to larger threat of eye illness: research
Folks with diabetes who have been taking GLP-1 medicine had a low however elevated threat of an age-related eye illness...
AI’s Position in Decoding the FDA’s New Regulatory Communications
> Hear on Spotify> Hear on Apple Podcasts> Hear on Amazon Music> Hear on iHeartIn a dynamic regulatory atmosphere, IQVIA’s...
Ascletis’s day by day zits pill set for China overview after Part III win
Over 50 million individuals within the US dwell with zits. Maxbelchenko by way of Shutterstock. Sagimet Bioscience’s denifanstat, a one-daily...
Novartis, Regeneron, J&J, most cancers analysis
Need to keep on prime of the science and politics driving biotech right now? Join to get our biotech e-newsletter in your...
The Decadent Present of Knowledge at ASCO25
The American Society for Medical Oncology’s Annual Assembly for 2025 is, if nothing else, completely overwhelming and omnipresent. If the...
BMS outlays $11bn to affix BioNTech’s improvement of bispecific most cancers drug
BMS and BioNTech at the moment are contestants in a fast-moving scientific area that appears to transcend conventional single-mechanism checkpoint...
Pharmalittle: We’re studying about authorized battles over state PBM legal guidelines, Merck pulling an software and extra
And so, one other working week will quickly draw to an in depth. Not a second too quickly, sure? That...
Jazz Is within the “Goldilocks Zone” With New Most cancers Knowledge at ASCO25
Rob Iannone confirmed me the ASCO 2025 identify tag he’s sporting. Under the road the place it says “Jazz Prescription...
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in illness development in mCRC
Pfizer’s Braftovi cur the chance of loss of life in first-line mixture remedy for BRAF V600E mCRC. Photograph by SOPA...
STAT+: Up and down the ladder: The most recent comings and goings
Employed somebody new and thrilling? Promoted a rising star? Lastly solved that hard-to-fill spot? Share the information with us, and...
